Qingfeng Pharmaceutical Group and the China Association Against Epilepsy (CAAE) officially signed a strategic collaboration agreement, committing to a five‑year partnership spanning discipline development, talent cultivation and public welfare assistance. Through these multi‑dimensional measures, the two parties aim to improve patient treatment outcomes and quality of life and to support the high‑quality development of epilepsy prevention and treatment in China.
Collaboration Milestone
| Item | Detail |
|---|---|
| Parties | Qingfeng Pharmaceutical Group; China Association Against Epilepsy (CAAE) |
| Agreement Type | Strategic collaboration agreement |
| Signing Date | 18 Oct 2026 |
| Duration | Five years |
| Cooperation Areas | Discipline development; talent cultivation; public welfare assistance |
| Objectives | Improve patient treatment outcomes and quality of life; support high‑quality development of epilepsy prevention and treatment in China |
Collaboration Scope & Objectives
- Discipline Development: The partnership will strengthen the professional foundation of epilepsy care in China through collaboration between the pharmaceutical group and the national specialty association.
- Talent Cultivation: The two parties will jointly support the training and development of clinical talent in epilepsy prevention and treatment over the five‑year term.
- Public Welfare Assistance: Assistance programs are aimed at improving patient treatment outcomes and quality of life, extending the collaboration beyond clinical science into patient support.
- National Health Alignment: The agreement is positioned to support the high‑quality development of epilepsy prevention and treatment in China, aligning corporate resources with the specialty community’s long‑term agenda.
Company Profile – Qingfeng Pharmaceutical’s CNS Franchise
- Therapeutic Focus: Qingfeng has built a product matrix spanning multiple categories and dosage forms in the central nervous system (CNS) field.
- Marketed Portfolio: To date, the company has 15 CNS chemical drugs approved for marketing, including 6 first‑to‑market generic drugs in China – evidence of execution speed in competitive generic filing.
- Strategic Positioning: The breadth across categories and dosage forms underpins Qingfeng’s status as a CNS‑specialized pharmaceutical group and a natural industry partner for the CAAE collaboration.
Innovation Pipeline – Four Class 1 Assets in Two Years
Over the past two years, Qingfeng has had 4 Class 1 chemical innovative drugs approved for clinical trials, demonstrating a long‑term and highly distinctive pipeline layout:
- KR23335 tablets – for the treatment of epileptic seizures.
- KR23343 tablets – for the treatment of epileptic seizures.
- KR23248 capsules – intended for schizophrenia.
- KR25102 for injection – intended for the treatment of moderate‑to‑severe acute pain.
The concentration of two Class 1 assets in epileptic seizures directly reinforces the strategic logic of the CAAE partnership, pairing specialty‑society engagement with an internally developed anti‑epileptic pipeline.
Market Impact & Outlook
- Epilepsy Franchise Synergy: The five‑year agreement positions Qingfeng closer to China’s epilepsy clinical community just as its KR23335 and KR23343 programs advance – potentially benefiting trial engagement, investigator relationships and future adoption.
- CNS Specialization Premium: With 15 marketed CNS chemical drugs, 6 first‑to‑market generics and 4 Class 1 INDs in two years, Qingfeng is building a differentiated CNS profile rare among Chinese regional pharmaceutical groups.
- Pipeline Diversification: The portfolio spans epilepsy, schizophrenia and acute pain, giving the company multiple shots on goal across high‑burden CNS indications (development timelines and trial data not disclosed).
- Public Welfare & Brand Equity: Participation in CAAE‑backed patient assistance and talent programs strengthens corporate reputation and aligns with China’s policy emphasis on chronic‑disease management and accessible care.
Forward‑Looking Statements
This brief contains forward‑looking statements regarding the strategic collaboration between Qingfeng Pharmaceutical Group and the China Association Against Epilepsy, and the clinical development of KR23335, KR23343, KR23248 and KR25102. Actual results may differ materially due to risks including clinical trial outcomes, regulatory review requirements, implementation of collaboration programs, and competitive dynamics. Clinical trial approval does not guarantee eventual marketing approval of any product.-Fineline Info & Tech
